PMID- 36525150
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221222
IS  - 2509-8020 (Electronic)
IS  - 2509-8020 (Linking)
VI  - 6
IP  - 1
DP  - 2022 Dec 16
TI  - Patients' self-management of adverse events and patient-reported outcomes in 
      advanced renal cell carcinoma treated with targeted therapies: A prospective, 
      longitudinal, observational study.
PG  - 125
LID - 10.1186/s41687-022-00532-0 [doi]
LID - 125
AB  - BACKGROUND: Early intervention to reduce the impact of adverse events (AEs) may 
      improve patients' quality of life and enable optimal treatment duration. METHODS: 
      This nationwide, multicenter, prospective, longitudinal, 1-year observational 
      study investigated patients' self-management of AEs associated with targeted 
      therapy for advanced renal cell carcinoma (RCC) and explored corresponding 
      outcomes, including treatment duration and patient-reported outcomes (PROs). 
      RESULTS: We enrolled 77 advanced RCC patients (mean age 62 years) treated with a 
      first targeted therapy. 210 cases of seven AEs of interest (fatigue, hand-foot 
      syndrome, oral mucosal inflammation, diarrhea, gastrointestinal symptoms, 
      hypertension, and anorexia) were observed. Most AEs were mild to moderate. 
      Overall, 63.4% of patients were identified as managing their AEs well, reporting 
      numerically longer treatment duration and significantly higher PRO scores than 
      patients identified as poor managers. CONCLUSIONS: Longer treatment duration and 
      improved PROs were observed when advanced RCC patients managed targeted 
      therapy-associated AEs well. Repeated education for consolidating AE 
      self-management could be considered to enhance overall treatment outcomes.
CI  - (c) 2022. The Author(s).
FAU - Hong, Sung-Hoo
AU  - Hong SH
AD  - Department of Urology, The Catholic University of Korea Seoul St. Mary's Hospital 
      at Seocho-gu, Seoul, Republic of Korea.
FAU - Chung, Ho Seok
AU  - Chung HS
AD  - Department of Urology, Chonnam National University Hwasun Hospital at Hwasun-gun, 
      Jeollanam-do, Republic of Korea.
FAU - Seo, Ill-Young
AU  - Seo IY
AD  - Department of Urology, Wonkwang University Hospital at Iksan, Jeonlabuk-do, 
      Republic of Korea.
FAU - Kwon, Tae Gyun
AU  - Kwon TG
AD  - Department of Urology, School of Medicine, Kyungpook National University, Daegu, 
      Republic of Korea.
FAU - Jeong, Hyeon
AU  - Jeong H
AD  - Department of Urology, SMG-SNU Boramae Medical Center at Dongjak-gu, Seoul, 
      Republic of Korea.
FAU - Chung, Jae-Il
AU  - Chung JI
AD  - Department of Urology, Inje University Busan Paik Hospital, Busanjin-gu, Busan, 
      Republic of Korea.
FAU - Jeon, Seung Hyun
AU  - Jeon SH
AD  - Department of Urology, Kyung Hee University School of Medicine at Dongdaemun-gu, 
      Seoul, Republic of Korea.
FAU - Park, Jae Young
AU  - Park JY
AD  - Department of Urology, Korea University Ansan Hospital at Ansan-si, Danwon-gu, 
      Gyeonggi-do, Republic of Korea.
FAU - Ha, Hong Koo
AU  - Ha HK
AD  - Department of Urology, Pusan National University Hospital at Seo-gu, Busan, 
      Republic of Korea.
FAU - Chung, Byung-Ha
AU  - Chung BH
AD  - Department of Urology, Gangnam Severance Hospital, Yonsei University Health 
      System at Gangnam-gu, Seoul, Republic of Korea.
FAU - Song, Wan
AU  - Song W
AD  - Department of Urology, Samsung Medical Center, Sungkyunkwan University School of 
      Medicine, Seoul, Republic of Korea.
FAU - Kim, Young-Joo
AU  - Kim YJ
AD  - Medical Division, Pfizer Biopharmaceuticals Group, Pfizer Pharmaceuticals Korea 
      Limited, Seoul, Republic of Korea.
FAU - Kim, Sang-Hee
AU  - Kim SH
AD  - Medical Division, Pfizer Biopharmaceuticals Group, Pfizer Pharmaceuticals Korea 
      Limited, Seoul, Republic of Korea.
FAU - Lee, Jee-Sun
AU  - Lee JS
AD  - Medical Division, Pfizer Biopharmaceuticals Group, Pfizer Pharmaceuticals Korea 
      Limited, Seoul, Republic of Korea.
FAU - Lee, Juneyoung
AU  - Lee J
AD  - Department of Biostatistics, College of Medicine, Korea University, Seoul, 
      Republic of Korea.
FAU - Chung, Jinsoo
AU  - Chung J
AUID- ORCID: 0000-0003-2251-5331
AD  - Center for Urologic Cancer, National Cancer Center, Goyang, Republic of Korea. 
      cjs5225@ncc.re.kr.
LA  - eng
PT  - Journal Article
DEP - 20221216
PL  - Germany
TA  - J Patient Rep Outcomes
JT  - Journal of patient-reported outcomes
JID - 101722688
PMC - PMC9758263
OTO - NOTNLM
OT  - Carcinoma
OT  - Molecular targeted therapy
OT  - Patient reported outcome measures
OT  - Renal cell
OT  - Self-management
OT  - Side effects and adverse reactions
COIS- Young-Joo Kim, Sang-Hee Kim and Jee-Sun Lee are employees of Pfizer 
      Pharmaceuticals Korea Ltd. We declare that the other authors have no competing 
      interests.
EDAT- 2022/12/17 06:00
MHDA- 2022/12/17 06:01
PMCR- 2022/12/16
CRDT- 2022/12/16 11:27
PHST- 2022/02/09 00:00 [received]
PHST- 2022/12/05 00:00 [accepted]
PHST- 2022/12/16 11:27 [entrez]
PHST- 2022/12/17 06:00 [pubmed]
PHST- 2022/12/17 06:01 [medline]
PHST- 2022/12/16 00:00 [pmc-release]
AID - 10.1186/s41687-022-00532-0 [pii]
AID - 532 [pii]
AID - 10.1186/s41687-022-00532-0 [doi]
PST - epublish
SO  - J Patient Rep Outcomes. 2022 Dec 16;6(1):125. doi: 10.1186/s41687-022-00532-0.